These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
423 related articles for article (PubMed ID: 29554076)
1. INSTRUMENTAL DIFFERENCE IN ASSESSING CHOROIDAL HYPERPERMEABILITY AND PHOTODYNAMIC THERAPY IN CHRONIC CENTRAL SEROUS CHORIORETINOPATHY. Lee SM; Kwon HJ; Park SW; Lee JE; Byon IS Retina; 2019 Jul; 39(7):1361-1369. PubMed ID: 29554076 [TBL] [Abstract][Full Text] [Related]
3. Clinical characteristics of chronic central serous chorioretinopathy patients with insufficient response to reduced-settings photodynamic therapy. van Rijssen TJ; van Dijk EHC; Dijkman G; Boon CJF Graefes Arch Clin Exp Ophthalmol; 2018 Aug; 256(8):1395-1402. PubMed ID: 29732468 [TBL] [Abstract][Full Text] [Related]
4. Comparison between the outcomes of fluorescein angiography-guided and indocyanine green angiography-guided half-time photodynamic therapy for central serous chorioretinopathy. Hayashida M; Miki A; Honda S; Nakamura M Photodiagnosis Photodyn Ther; 2020 Sep; 31():101955. PubMed ID: 32818640 [TBL] [Abstract][Full Text] [Related]
5. Photodynamic therapy in chronic central serous chorioretinopathy with subretinal fluid outside the fovea. van Dijk EHC; Dijkman G; Boon CJF Graefes Arch Clin Exp Ophthalmol; 2017 Oct; 255(10):2029-2035. PubMed ID: 28674835 [TBL] [Abstract][Full Text] [Related]
6. OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY-GUIDED PHOTODYNAMIC THERAPY FOR ACUTE CENTRAL SEROUS CHORIORETINOPATHY. Hu J; Qu J; Li M; Sun G; Piao Z; Liang Z; Yao Y; Sadda S; Zhao M Retina; 2021 Jan; 41(1):189-198. PubMed ID: 32343102 [TBL] [Abstract][Full Text] [Related]
7. Effect of Photodynamic Therapy on Optical Coherence Tomography Angiography in Eyes with Chronic Central Serous Chorioretinopathy. Xu Y; Su Y; Li L; Qi H; Zheng H; Chen C Ophthalmologica; 2017; 237(3):167-172. PubMed ID: 28171871 [TBL] [Abstract][Full Text] [Related]
8. COMPARISON OF PHOTODYNAMIC THERAPY USING HALF-DOSE OF VERTEPORFIN OR HALF-FLUENCE OF LASER LIGHT FOR THE TREATMENT OF CHRONIC CENTRAL SEROUS CHORIORETINOPATHY. Cheng CK; Chang CK; Peng CH Retina; 2017 Feb; 37(2):325-333. PubMed ID: 27429374 [TBL] [Abstract][Full Text] [Related]
9. Half-dose photodynamic therapy followed by diode micropulse laser therapy as treatment for chronic central serous chorioretinopathy: evaluation of a prospective treatment protocol. Breukink MB; Mohr JK; Ossewaarde-van Norel A; den Hollander AI; Keunen JE; Hoyng CB; Boon CJ Acta Ophthalmol; 2016 Mar; 94(2):187-97. PubMed ID: 26670630 [TBL] [Abstract][Full Text] [Related]
10. Subfoveal choroidal thickness after treatment of central serous chorioretinopathy. Maruko I; Iida T; Sugano Y; Ojima A; Ogasawara M; Spaide RF Ophthalmology; 2010 Sep; 117(9):1792-9. PubMed ID: 20472289 [TBL] [Abstract][Full Text] [Related]
11. Efficacy of half-fluence photodynamic therapy depending on the degree of choroidal hyperpermeability in chronic central serous chorioretinopathy. Lim SH; Chang W; Sagong M Eye (Lond); 2013 Mar; 27(3):353-62. PubMed ID: 23449515 [TBL] [Abstract][Full Text] [Related]
12. Long-Term Outcomes of Full-Fluence and Half-Fluence Photodynamic Therapy for Chronic Central Serous Chorioretinopathy. Son BK; Kim K; Kim ES; Yu SY Ophthalmologica; 2019; 241(2):105-115. PubMed ID: 30110697 [TBL] [Abstract][Full Text] [Related]
13. Association between the efficacy of half-dose photodynamic therapy with indocyanine green angiography and optical coherence tomography findings in the treatment of central serous chorioretinopathy. Nicolò M; Zoli D; Musolino M; Traverso CE Am J Ophthalmol; 2012 Mar; 153(3):474-480.e1. PubMed ID: 22019224 [TBL] [Abstract][Full Text] [Related]
14. Low-fluence photodynamic therapy versus ranibizumab for chronic central serous chorioretinopathy: one-year results of a randomized trial. Bae SH; Heo J; Kim C; Kim TW; Shin JY; Lee JY; Song SJ; Park TK; Moon SW; Chung H Ophthalmology; 2014 Feb; 121(2):558-65. PubMed ID: 24268858 [TBL] [Abstract][Full Text] [Related]
15. A randomized pilot study of low-fluence photodynamic therapy versus intravitreal ranibizumab for chronic central serous chorioretinopathy. Bae SH; Heo JW; Kim C; Kim TW; Lee JY; Song SJ; Park TK; Moon SW; Chung H Am J Ophthalmol; 2011 Nov; 152(5):784-92.e2. PubMed ID: 21742303 [TBL] [Abstract][Full Text] [Related]
17. Long-term follow-up of chronic central serous chorioretinopathy after successful treatment with photodynamic therapy or micropulse laser. van Rijssen TJ; van Dijk EHC; Scholz P; Breukink MB; Dijkman G; Peters PJH; Tsonaka R; Keunen JEE; MacLaren RE; Hoyng CB; Downes SM; Fauser S; Boon CJF Acta Ophthalmol; 2021 Nov; 99(7):805-811. PubMed ID: 33565230 [TBL] [Abstract][Full Text] [Related]
18. Reduced-fluence photodynamic therapy for subfoveal serous pigment epithelial detachment with choroidal vascular hyperpermeability. Goto S; Gomi F; Ueno C; Nishida K Am J Ophthalmol; 2012 Nov; 154(5):865-871.e1. PubMed ID: 22840480 [TBL] [Abstract][Full Text] [Related]
19. Multimodal Imaging and Choroidal Volumetric Changes After Half-fluence PDT in Central Serous Chorioretinopathy. Munk MR; Shah R; Pappas F; Baddar D; Wong B; Jampol LM; Fawzi AA Curr Eye Res; 2016; 41(1):97-106. PubMed ID: 25612245 [TBL] [Abstract][Full Text] [Related]
20. Clinical research on one-third dose verteporfin photodynamic therapy in the treatment of chronic central serous chorioretinopathy. Hua L; Lin B; Hong J; Min HB; Han WL; Zhou TY; Zhang ZQ Eur Rev Med Pharmacol Sci; 2018 Jan; 22(2):278-284. PubMed ID: 29424884 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]